Premium
Effect of a Vitamin D supplement on circulating Vitamin D status in pre‐ and post‐menopausal women: a randomized controlled trial
Author(s) -
Laidlaw Maggie,
Cockerline Carla Ann,
Almada Anthony L.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.214.2
Subject(s) - placebo , medicine , vitamin d and neurology , vitamin , breast cancer , incidence (geometry) , repeated measures design , randomized controlled trial , physiology , analysis of variance , endocrinology , cancer , statistics , physics , alternative medicine , mathematics , pathology , optics
Objectives The major trial objective was to determine whether a Vitamin D supplement would raise circulating 25(OH) Vitamin D concentration to a level favourable to a reduction in breast cancer incidence. Methods Forty‐seven pre‐menopausal and forty‐nine post‐menopausal women were recruited for this study, and were divided by random allocation into treatment and placebo group. The treatment contained 400 I.U. (10 micrograms) Vitamin D, and each woman consumed either treatment or placebo for 28 days. At day 0 and day 28, blood samples were analysed for serum 25(OH) Vitamin D concentrations, and repeated measures ANOVA statistical testing was performed. Results In both pre‐ and post‐menopausal women, supplementation with 400 I.U. of Vitamin D per day did not significantly alter circulating 25(OH) Vitamin D concentrations. Conclusions The treatment supplement was tested for Vitamin D level, subjects in the trial were fully were compliant with the protocol and consumed their supplement with meals, and there was a low likelihood of interaction of the supplement with other supplement ingredients. Therefore, it appears that an additional 400 I.U of Vitamin D in the diets of pre‐ and post‐menopausal women is not sufficient to raise circulating 25(OH) Vitamin D concentrations to the minimum level commensurate with a 50% reduction in breast cancer incidence, i.e. 52 ng/ml (130 mmol/L). Research Support: Fem Med Formulas Limited Partnership